Market closed
Erasca/$ERAS
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Erasca
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.
Ticker
$ERAS
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
103
Website
Erasca Metrics
BasicAdvanced
$347M
-
-$0.69
1.22
-
Price and volume
Market cap
$347M
Beta
1.22
52-week high
$3.45
52-week low
$1.01
Average daily volume
1.7M
Financial strength
Current ratio
9.836
Quick ratio
9.575
Long term debt to equity
11.162
Total debt to equity
12.252
Management effectiveness
Return on assets (TTM)
-21.22%
Return on equity (TTM)
-43.68%
Valuation
Price to book
0.82
Price to tangible book (TTM)
0.82
Price to free cash flow (TTM)
-2.17
Growth
Earnings per share change (TTM)
-16.96%
3-year earnings per share growth (CAGR)
-28.00%
What the Analysts think about Erasca
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Erasca stock.
Erasca Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
Erasca Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Erasca News
AllArticlesVideos
Erasca Presents New Preclinical Data Reinforcing Best-in-Class Potential of RAS-Targeting Franchise at the 2025 AACR Annual Meeting
GlobeNewsWire·1 week ago
Erasca, Inc.: Carving A Different Niche In RAS Signaling
Seeking Alpha·2 weeks ago
Erasca Announces Three Poster Presentations at the 2025 AACR Annual Meeting
GlobeNewsWire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Erasca stock?
Erasca (ERAS) has a market cap of $347M as of May 09, 2025.
What is the P/E ratio for Erasca stock?
The price to earnings (P/E) ratio for Erasca (ERAS) stock is 0 as of May 09, 2025.
Does Erasca stock pay dividends?
No, Erasca (ERAS) stock does not pay dividends to its shareholders as of May 09, 2025.
When is the next Erasca dividend payment date?
Erasca (ERAS) stock does not pay dividends to its shareholders.
What is the beta indicator for Erasca?
Erasca (ERAS) has a beta rating of 1.22. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.